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Abstract
Migration of dendritic cells (DC) from the tumor environment to the T cell cortex in tumor-draining lymph nodes (TDLN) is
essential for priming naı ¨ve T lymphocytes (TL) to tumor antigen (Ag). We used a mouse model of induced melanoma in
which similar oncogenic events generate two phenotypically distinct melanomas to study the influence of tumor-associated
inflammation on secondary lymphoid organ (SLO) organization. One tumor promotes inflammatory cytokines, leading to
mobilization of immature myeloid cells (iMC) to the tumor and SLO; the other does not. We report that inflammatory
tumors induced alterations of the stromal cell network of SLO, profoundly altering the distribution of TL and the capacity of
skin-derived DC and TL to migrate or home to TDLN. These defects, which did not require tumor invasion, correlated with
loss of fibroblastic reticular cells in T cell zones and in impaired production of CCL21. Infiltrating iMC accumulated in the
TDLN medulla and the splenic red pulp. We propose that impaired function of the stromal cell network during chronic
inflammation induced by some tumors renders spleens non-receptive to TL and TDLN non-receptive to TL and migratory
DC, while the entry of iMC into these perturbed SLO is enhanced. This could constitute a mechanism by which inflammatory
tumors escape immune control. If our results apply to inflammatory tumors in general, the demonstration that SLO are
poorly receptive to CCR7-dependent migration of skin-derived DC and naı ¨ve TL may constitute an obstacle for proposed
vaccination or adoptive TL therapies of their hosts.
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Introduction
The generation of immune responses requires interaction of
rare antigen (Ag)-specific T lymphocytes (TL) with DC presenting
relevant Ag. Interactions occur in secondary lymphoid organs
(SLO) and are highly dependent on their architecture [1]. In SLO,
T cell zones (T-zones) contain specialized fibroblastic cells [2], the
organization of which maximizes the probability that TL
encounter the DC presenting the cognate Ag [3]. Stromal cells,
including fibroblastic reticular cells (FRC) present in T-zones and
follicular dendritic cells (FDC) present in B-zones, secrete
chemokines that recruit and organize distinct zones. CCL21/
CCL19 recruit CCR7-expressing TL and DC in T-zones, whereas
CXCL13 is critical for B-zone formation [2,4,5]. Additionally,
FRC secrete other factors necessary for the homeostasis of
lymphocytes, such as IL-7 [6] and support TL migration in the
LN and spleen [7,8].
Spontaneous or vaccination-induced tumor-specific immune
responses do not develop or are insufficient in patients and in
experimental animals with advanced cancers. Several possible
explanations for this poor reactivity to tumor Ag have been
presented. First, tumor Ag may not be adequately presented in the
absence of DC-activation signals evolutionarily associated with
infectious agents. This leads to TL ‘‘ignorance’’ or tolerance rather
than induction of effector functions [9]. Second, tumor develop-
ment is often associated with inflammation [10,11], and tumors
may secrete tumor derived factors (TDF) that directly impede
immune reactions. Some TDF, such as TGFb, may affect TL
differentiation (reviewed in [12]). Others, such as GM-CSF, may
alter DC differentiation [13]. Little is known about possible
impacts of TDF on SLO architecture and their consequences for
anti-tumor responses. Third, immune suppression in cancer has
also been associated with the accumulation in blood, lymphoid
organs and tumor of immature-type myeloid cells (iMC), also
called myeloid suppressor cells (MDSC) (reviewed in [14]).
Originating in the bone marrow, these iMC express Gr1 and
CD11b in the mouse. Under normal conditions iMC differentiate
into DC, macrophages or granulocytes, but their differentiation
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as yet addressed the relationship between accumulation of iMC in
cancer and SLO structure.
To study the influence of TDF on SLO organization, we used a
model of induced melanoma in which similar oncogenic events
induce two phenotypically distinct melanomas, both expressing
cancer-germline gene P1A concomitant with the induction of
oncogenesis [16]. One tumor is poorly pigmented (referred to as
Amela), promotes high levels of inflammatory cytokines system-
ically and induces chronic inflammation, leading to an important
mobilization of iMC to the tumor and SLO, whereas the other,
highly pigmented (referred to as Mela), does not [17]. The
immune system of mice with induced slow progressing Mela
tumors appeared to be ‘‘ignorant’’ of the tumor but not
suppressed, as these mice remained capable of responding to
and of rejecting a P1A-expressing transplanted tumor line
originating from an induced melanoma. In mice with aggressively
progressing induced Amela tumors associated with inflammation,
however, the immune system was suppressed and was incapable of
rejecting the P1A-expressing transplanted tumor [17].
In this report we provide evidence that tumors associated with
inflammation induce alterations of the stromal cell network of
SLO. This remodeling during autochthonous tumor development
profoundly alters both TL distribution in the spleen and in TDLN
and the capacity of skin-derived DC to migrate to TDLN.
Consequently, SLO architecture disruption may have an impact
on the successful establishment of immunotherapeutic strategies
because it impedes TL and DC localization in T-zones. Affecting
stromal cell networks in SLO constitutes a new mechanism by
which tumors might escape immune control.
Results
Impaired recruitment of skin-derived DC in TDLN of mice
developing Amela-melanomas
DC take up Ag and migrate from peripheral tissues via afferent
lymphatics into T cell areas of draining lymph nodes (DLNs), where
they may activate cognate TL. We previously observed that P1A-
specific TCRP1A TL [18] adoptively transferred in mice with P1A-
expressing induced inflammatory Amela-melanomas were poorly
activated in TDLN of these mice [17]. Since TDF can affect DC
differentiation [19], we analyzed DC subpopulations present in
TDLN of these mice. Skin-DLN contain DC subsets of different
origins [20,21]. These include migratory DC (MigDC), composed
of skin-derived epidermal Langerhans cells and dermal DC [22], as
well as lymphoid resident DC (ResDC), found in all lymphoid
tissues. Cutaneous LN MigDC are CD11c
+MHCII
high while
ResDC are CD11c
highMHCII
intermediate ([23], and Fig.1). Using
flow cytometry, we observed a significant decrease in MigDC
compared to ResDC in TDLN of Amela-bearing mice (Fig.1A).
Such a defect was not observed in TDLN from Mela-bearing mice,
and was less drastic in contra-lateral as opposed to TDLN from
Amela-bearing mice (Fig.S1A-C). By immunohistology (Fig.S1D),
MHCII
high cells were observed in the T cell zone in control LN and
in Mela-TDLN, whereas they were dispersed in Amela-TDLN.
To evaluate the basis for the selective paucity of MigDC in Amela-
TDLN, we compared migratory behavior of skin-derived DC from
control and tumor-bearing mice. We painted tumor and surrounding
skin of mice with induced melanomas or normal skin from control
mice with TRITC (see methods). Twenty hours later we analyzed the
DC migration into DLN [19]. This showed lower recruitment of
TRITC
+ M i g D Ci nA m e l a - T D L Nt h a ni nc o n t r o lL N s( F i g . 1 B – D ) .
Migration of DC from the skin to LNs, notably through dermal
lymphatics, depends on their expression of CCR7 under both
steady state and inflammatory conditions [24]. This was
confirmed, in particular for the CD207/langerin
+ skin-derived
DC subpopulation [25]. Deficient CCR7 expression could thus be
a cause of defective migration of skin-derived DC to TDLN [26].
To test this possibility, using the TRITC-painting protocol, we
compared the level of expression of CCR7 on steady state
(TRITC
2) and on recently migrated (TRITC
+) DC subpopula-
tions (Fig.1C–F). As expected, within the TRITC
2 fraction, we
could identify the ResDC as well as the CD207
2 and CD207
+
MigDC subpopulations, whereas only the MigDC subpopulations
were present in the TRITC
+ fraction whether in control LN or in
TDLN (Fig.1C–D). CCR7 expression was lowest on the ResDC
populations and highest on the CD207
+ MigDC populations in
both control LN (Fig.1E) and Amela-TDLN (Fig.1F). The latter
expressed similarly high levels of CCR7 in both the TRITC
2
steady state and the recently migrated TRITC
+ populations. The
CD207
2 MigDC expressed intermediate CCR7 levels whether in
control LN or in TDLN. It should be noted that in the absence of
analysis of DC subpopulations, CCR7 expression would have
appeared lower in the Amela-TDLN than in control LNs, given
that ResDC with low CCR7 expression are enriched relative to
MigDC in the Amela-TDLN.
The analysis of CCR7 expression on DC subsets thus revealed
that although the MigDC subpopulations were under-represented
in the Amela-TDLN, their surface expression of CCR7 was as
high as on their counterparts in normal cutaneous LN.
Among other possible causes for poor migration or localization
of DC in DLN is the absence of CCR7 ligands, as shown in mice
deficient in CCL19 and CCL21-Ser [27]. Such defects would also
be expected to affect TL localization in TDLN. This possibility
was analyzed next.
Impaired T cell localization in TDLN of mice developing
Amela-melanomas
To examine whether migration of naı ¨ve TL in TDLN is
affected, CFSE-labeled naı ¨ve CD8 TL were i.v. injected in control
and in Mela- and Amela-developing mice. Mice were sacrificed
15hrs later and LN sections were analyzed by immunohistology.
Staining with anti-CD3 and anti-B220 monoclonal antibody
(mAb) to detect, respectively, the T-zones and B-zones of the LN
was performed (Fig.2A). In control and Mela-bearing mice,
defined B- and T-zones were apparent and CFSE-labeled TL
co-localized with the endogenous TL. In Amela-bearing mice,
however, some B-zones were visible, but no defined T-zones were
apparent. CFSE-labeled TL were distributed throughout the LN.
Analysis of LN sections from different mice showed that the total
number of TL per section area in LN of the hosts was significantly
reduced in Amela-bearing mice (graph in Fig.2A).
The migration of the CFSE-labeled TL in the spleen was also
evaluated by immunohistology (Fig.2B) on sections labeled with anti-
B220 or MOMA-1 antibody identifying metallophilic macrophages
adjacent to the marginal zone of the spleen, which is the region at the
interface between non-lymphoid red pulp and lymphoid white-pulp
[28]. In control and Mela-bearing mice transferred naı ¨ve TL
localizedpredominantlytothewhitepulpareaoutlinedbyMOMA-1
positive cells. In contrast, in Amela-bearing mice transferred TL had
a diffuse distribution throughout the spleen. Data for a number of
splenic sections from different mice are shown (Fig.2B).
We next examined expression of CCR7, the main chemokine
receptor necessary for appropriate location of TL to SLO and
found similar levels on TL present in control LNs, Mela- or
Amela-TDLN (Fig.S2).
The results indicate that localization of endogenous as well as of
adoptively transferred naı ¨ve TL is perturbed in TDLN and in
Inflammatory Melanomas Disrupt Lymphoid Stroma
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appear to be intrinsic to the TLs, but might result from SLO
disorganization.
Disruption of lymphoid organization and decrease of
T- and B-zones in mice developing Amela-melanomas
To further evaluate the defect in organization of SLO in Amela-
bearing mice, we assessed quantitatively T and B cell areas in a
number of sections of TDLN from different tumor-bearing mice or
of LN from different control mice using ImagJ software. While T
cell areas represent more than 15% of LN area in control or in
Mela-TDLN, they represent less than 5% of the area in Amela-
TDLN (graph in Fig.3A). No statistically significant decrease in B
cell area fractions was observed in Amela-TDLN (graph in Fig.3A).
For spleen sections (Fig.3B), quantification of white pulp size
(graph in Fig.3B) showed a significant reduction in Amela-bearing
mice compared with control or Mela-bearing mice correlated with
a decreased area fraction of T and B cells (graphs in Fig.3B).
Figure 1. Recruitment of skin-derived DC in mice developing Amela-melanomas is impaired, but their expression of CCR7 is
unaltered. (A) Ratio of MigDC versus ResDC in Amela-TDLN or corresponding LN from control mice. (B) % TRITC-labeled cells among MigDC in
Amela-TDLN or corresponding LN from control mice 20 hrs after TRITC-skin painting (see Methods). (C-F) Analysis of DC subpopulations in LNs from
control (C, E) or Amela-bearing (D, F) mice after TRITC-painting. (C-D) After gating on CD11c
+NK1.1
2CD25
2CD45R
2 cells, TRITC-staining is shown
versus SSC. TRITC
– and TRITC
+ cells were analyzed for expression of CD11c versus MHCII. ResDC and MigDC were found within TRITC
2 cells; only
MigDC were found within TRITC
+ cells. Only MigDC expressed CD207 corresponding to Langerhans cells and CD207
+ Dermal DC. (E–F) Histograms of
CCR7 expression for the different DC subpopulations indicated in C and D, respectively, show low, intermediate and high fluorescence values (mean),
respectively, for ResDC, CD207
2MigDC and CD207
+MigDC.
doi:10.1371/journal.pone.0022639.g001
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decreased in Amela-bearing mice (Table S1). This observation
means that in Amela-bearing mice splenic TL did not form
follicles, as in control mice, but were dispersed throughout the
spleen, and in particular in the red pulp.
Loss of gp38+ FRC-associated CCL21 in spleens and
TDLN of mice developing Amela-melanomas
B- and T-zones of SLO are organized by the expression of
homeostatic chemokines by defined fixed stromal cells: FDC
secreting CXCL13 and FRC secreting CCL19 and CCL21,
respectively in B- and T-zones [5,29]. FRC, as many fibroblasts,
express a molecule recognized by mAb ER-TR7 [30], as well as
podoplanin (gp38) [31]. We analyzed expression of CCL21 on
sections of spleens together with ER-TR7 and B220 staining
(Fig.4A). Interestingly we observed an important decrease in
expression of CCL21 in spleens from Amela-bearing mice. QRT-
PCR analysis (Fig.4B) further showed reduced expression of both
CCL21-Ser and CCL19 transcripts in spleen samples from Amela-
bearing mice, whereas expression of CXCL13 transcripts was not
affected.
To address the question whether the decrease in CCL21 is the
consequence of a reduction in T-zone associated FRCs, we
performed immunohistology for detection of gp38 and CCL21
together with ER-TR7 on splenic sections (Fig.5A). Results
showed that the density of gp38+ cells was greatly decreased, as
was CCL21 detection in spleens of Amela-bearing mice as
compared to those of control or Mela-bearing mice. A similar
analysis performed on LN sections showed co-localization of
CCL21 staining with gp38 expression in the T-zones for control
LN and Mela-TDLN (Fig.5B). In Amela-TDLN, however, the
density of gp38+ cells was increased, but they were not associated
with CCL21 expression. These strongly gp38+ cells probably
corresponded to endothelial cells and were not restricted to the T
cell zone, as reported [6]. Punctate CCL21 staining was detected
in areas that are distinct from the gp38-associated CCL21 staining
observed in control LN and in Mela-TDLN (Fig.5B).
Altogether, our results show that the reduced T-zones in spleen
and TDLN, are associated with a reduction in CCL21+gp38+
FRCs.
The architecture of SLO is disrupted in mice developing
Amela-melanomas
FRC are also implicated in production of reticular fibers that
organize SLO [32]. We next addressed the question of the
integrity of the SLO architecture in Amela-bearing mice. FRC
Figure 2. TL localization in TDLN of mice developing Amela-melanomas is impaired. (A) CFSE-labeled CD8 TL from B10.D2 mice (white)
were adoptively transferred into control, Mela- and Amela-bearing recipient mice. 15 hrs later their LN (A) were stained with anti-B220-PE-Texas red
(red) and anti-CD3-APC (blue) and spleens (B) were stained with anti-B220-APC (blue) (upper pictures) or anti-MOMA-1-biotyl/streptavidin-Alexa647
(blue) (lower pictures) and analyzed by confocal microscopy (see Methods). The graph in (A) represents the number of CFSE+ cells per section of LN.
The graph in (B) represents the number of CFSE+ cells per splenic white pulp. Number of white pulps analyzed per mouse was . or =2. Data are
from 8 (control), 3 (Mela-bearing) and 4 (Amela-bearing) mice. Statistics are as described in Methods.
doi:10.1371/journal.pone.0022639.g002
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molecular weight molecules from the periphery are trapped
[33,34]. The surface of this conduit also guides TL migration [7].
Thus, it is important for the adequate localization of cells in SLO
that this complex network be well conserved. By staining sections
of SLO for different elements of the FRC network (Fig.6A), we
observed in spleens of both control and Mela-bearing mice that
the ER-TR7 positive network defined a dense group of fibers
Figure 3. Lymphoid organization in developing Amela-melanomas is disrupted. Analysis of LN (A) and spleen (B) from control, Mela- and
Amela-bearing mice. (A) In LN, B- and T-zones were identified with anti-B220-PE-Texas red (red) and anti-CD3-FITC (green), respectively. Graphs
represent the density of B (left) and T (right) cells, determined by pixel quantification. For tumor-bearing mice, TDLN are shown. Data are from 7
(control), 4 (Mela-bearing) and 4 (Amela-bearing) mice. (B) Splenic B-zones, T-zones and marginal zones were identified with anti-B220-APC (blue),
anti-CD3-FITC (green), and anti-MOMA-1/goat anti-rat-Alexa647 (red), respectively. The white pulp areas are delineated by MOMA-1 expression. One
graph (left) shows the size of white pulp areas in the different mice (each symbol represents a white pulp area). Density of B (middle graph) and T
(right graph) cells were determined by pixel quantification. Data are from 6 (control), 4 (Mela-bearing) and 9 (Amela-bearing) mice.
doi:10.1371/journal.pone.0022639.g003
Inflammatory Melanomas Disrupt Lymphoid Stroma
PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22639localized in the red pulp and a less dense network in the white
pulp, as described (reviewed in [29]). However, in Amela-bearing
mice this network seemed to be less dense, as well as
discontinuous, with shorter fibers. We analyzed expression of
other molecules that compose the network, such as laminin and
collagen IV. The results were similar to those seen for ER-TR7, in
particular for laminin. The different staining experiments show
that the splenic stromal cell network is disrupted in Amela-bearing
mice (Fig.6A).
FRC also have a contractile function and share certain features
with smooth muscle cells or myofibroblasts [6,29]. Consequently,
we investigated the possibility that alteration of the stromal cell
network might be associated with reduction of cells with contractile
activity. Staining for desmin expression (Fig.6B), indeed, revealed a
loss of desmin
+ cells in spleens of Amela-bearing mice. Thus, in
association with the decrease in the area of gp38
+ cells, which in
spleens characterize FRC of T-zones, we observed a loss of FRC, in
particular, the desmin+ fraction of FRC. In addition to being
enlarged, the splenic red pulp of Amela-bearing mice is thus also
altered phenotypically. To rule out the possibility that metastasis of
melanoma, although not visible, might induce the disruption of the
splenic architecture, we tested for presence of transcripts of the
oncogene H-Ras
G12V which isexpressed bytheinducedmelanomas
(QRT-PCR, data not shown). However, we failed to detect
expression of H-Ras
G12V transcripts in spleens from Amela-bearing
mice, so this hypothesis seems unlikely.
The LN stromal network, although reminiscent of that of the
spleen, presents some differences. As for the splenic red pulp, the LN
medulla presents a dense ER-TR7+ network whereas the LN T-zone
ER-TR7+ network is less dense [5,29]. In LN, however, desmin is
highly expressed in the T-zones ([6], Fig.S3A–B). In Amela-bearing
mice, the discontinued network fibers observed in the spleen are not
consistently observed in the TDLN. However, in these mice we
always noticed an enlargement in the medullar and a decrease in the
T-zone networks in TDLN. Furthermore the desmin+ER-TR7+
fibers characteristic of T-zones in control and Mela-TDLN are
reduced and morphologically different in Amela-TDLN (Fig.S3B).
CD11b
+Gr1
+ iMC localized in LN medulla and spleen red
pulp interact with the stromal network in mice
developing Amela-melanomas
We reported that CD11b
+Gr1
+ cells accumulate in SLO of
Amela-bearing mice [17]. To evaluate the potential impact of
these iMC on SLO organization in Amela-bearing mice, we
analyzed localization of CD11b
+Gr1
+ cells in SLO and, in
particular, investigated whether accumulation of these cells
correlated with alteration of SLO architecture (Fig.7A–D).
Sections of LN and spleens were stained with antibodies to Gr1.
For LN we used the Lyve-1 marker of lymphatic endothelial cells to
define the medulla, and for spleens the MOMA-1marker to localize
the white pulp (Fig.7A–B). Most Gr1
+ cells were localized in LN
medulla and in splenic red pulp in all samples. As we observed a
destruction of the stromal cell network in SLO of Amela-bearing
mice, we wondered whether CD11b
+Gr1
+ cells could interact with
the network. To this end we stained LN and spleen sections for ER-
TR7 and Gr1 markers (Fig.7C–D). We observed that Gr1
+ cells
were associated with remnants of the stromal cell network, in
particular in the spleen (Fig. 7D), as described for lymphocytes that
use it for their guidance and motility [7,8].
CD11b
+Gr1
+ cells also appeared to form clusters in spleens and
Amela-TDLN (Fig.S4), possibly the consequence of either their
Figure 4. Decrease in splenic lymphoid chemokines in mice developing Amela-melanomas. Spleen sections from control, Mela- and
Amela-bearing mice stained in (A) with anti-B220-APC (blue) to detect the B-zone, ER-TR7/chicken anti-rat-Alexa488 (green) to detect the FRC
network and anti-CCL21/donkey anti-goat-Alexa546 (red). (B) Expression of ccl21a encoding Ccl21-Ser, ccl19 and cxcl13 relative to tbp transcripts
measured by QRT-PCR in total spleens of control, Mela- or Amela- bearing mice. Means (+/2 s.e.m.) for independent samples (N=10; 8; 14 for ccl21a;
N=5; 4; 8 for ccl19; N=3; 3; 9 for cxcl13) from spleens of control, Mela- or Amela- bearing mice, respectively, A is representative of 5 mice per group.
doi:10.1371/journal.pone.0022639.g004
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To discriminate between these two possibilities, we stained spleen,
LN and control skin or Amela-tumors for the proliferation marker
Ki-67. No colocalization between the Ki-67 and Gr1+ markers
was detected in spleen, LN or tumor/tissue (Fig.S4). This
observation suggests that the clustering of Gr1+ cells in SLO is
due to the recruitment of iMC cells from the bone marrow in
Amela-bearing mice. In the spleen, they are localized in the red
pulp where they closely interact with the stromal cell network. In
the Amela-TDLN, the CD11b
+Gr1
+ cells are found in the
medulla, where they may have migrated either from the blood
or from the tumor tissue. This observation is reminiscent of that
described for neutrophils [35] in a model of parasite infection. The
fact that principally TDLN are affected in their organization and
in recruitment of iMC may suggest that LN are less influenced by
the systemic effects of TDF, but are rather under the local
influence of TDF and recruited cells.
Discussion
Defects in DC differentiation have been observed in both cancer
patients and tumor bearing mice [36]. Evidence exits for a
Figure 5. Loss of gp38+ FRC-associated CCL21 in spleens and TDLN of mice developing Amela-melanomas. In (A) spleen sections were
stained with ER-TR7/chicken anti-rat-Alexa647 (blue), anti-gp38/donkey anti-goat-Alexa488 (green) and anti-CCL21-biotyl/SA-Alexa546 (red). In (B) LN
sections were stained with anti-B220-Alexa647 (blue), anti-gp38/donkey anti-goat-Alexa546 (red) and anti-CCL21-biotyl/SA-Alexa488 (green). A and B
are representative of 3 mice per group. Lower images show magnifications of the fields highlighted in the upper images and show stainings with
each of the antibodies separately and merged, as indicated.
doi:10.1371/journal.pone.0022639.g005
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other explanations for the paucity of mature DC in TDLN include
DC killing by Treg [37] and down-regulation of CCR7 surface
expression, required for DC migration from skin to LN [26].
However, these studies failed to analyze distinct DC subpopula-
tions differing in their origin and level of CCR7 expression [23].
Analysis of these subpopulations in TDLN reported here in
mice with autochthonous inflammatory melanomas revealed
selective reduction in populations of MigDC compared to
lymphoid tissue-ResDC. The reduced fraction of MigDC
migrating to TDLN 20 hrs after skin painting is consistent with
a defect in their migration and/or homing to LN rather than (or in
addition to) a systemic perturbation of DC differentiation in these
mice. No evidence for CCR7 down-modulation was observed in
any MigDC subpopulation in the present study.
Migration of skin-derived DC from afferent lymphatics into LN
T-zones is guided by CCL19 and CCL21-ser (encoded by gene
ccl21a) expressed by T-zone FRC [6]. In plt/plt (plt, paucity of LN
T cells) mice, which lack expression of CCL19 and CCL21-ser,
MigDC are strongly reduced in skin-DLN despite expression of
CCL21-leu, encoded by gene ccl21c by peripheral lymphatic
vessels [27,38]. In the autochthonous Amela-melanoma model,
splenic reduction in CCL19 and CCL21 transcripts was associated
with loss of gp38+ FRC, generating a phenotype similar to that of
plt/plt mice with a defect in recruitment of naı ¨ve TL. In TDLN
gp38+ cells were abundantly detected, which probably corre-
sponded to lymphoid endothelial cells [6]. These cells were not
associated with CCL21, as is the case for the gp38+ FRCs found in
T-zones of control LN and these TDLN presented defects in
recruitment of both CCR7
+ MigDC and TL.
A progressive decrease in CCL21 production in TDLN of mice
with growing transplanted melanomas was also previously
associated with impaired recruitment of naı ¨ve TL in LN,
independent of LN metastasis [39]. Suppression of CCL21
production was also reported in TDLN of patients with metastatic
melanoma [40]. Disruption of LN architecture as a result of down-
regulation of both CCL21 and CXCL13 appeared to increase the
virulence of Salmonella [41].
In the Amela-melanoma model, reduction of T-zones was
associated with a loss of gp38+ FRCs and CCL21 in those zones.
In addition, marked invasion of SLO with iMC was observed. In a
previous study [39], Gr1
+ polymorphonuclear cells appeared to
invade the medulla, upper cortex and capsule of transplanted
melanoma-TDLN with decreased CCL21 expression.
Our study reveals that important alterations of SLO architec-
ture occur during autochthonous inflammatory tumor develop-
ment. It identifies multiple defects apparently induced by Amela-
tumors that could explain the reduction in T-zone area in SLO of
tumor-bearing mice. Of note, adaptive immune responses are
generally associated with a down-regulation of CCL21 production
by FRC [42], but this effect was transient and was attributed to
IFN-c, a cytokine that is not produced in Amela-bearing mice
[17].
Other mechanisms may be involved in the context of
inflammatory tumor development. The Amela tumor secretes
several factors implicated in SLO remodeling, including VEGF
and FGF-2 [17]. These TDF could contribute to the important
lymphangiogenesis in Amela-TDLN, since stromal cells present in
the LN medulla and splenic red pulp of Amela-bearing mice might
express VEGFR2 (Fig.S5). Systemic effects of VEGF on splenic
organization were reported in mice transplanted with tumors over-
expressing VEGF [43]. The increase in size of the splenic red pulp
or LN medulla could contribute to decreases of splenic white pulp
or LN T-zones, respectively. Additionally, a paucity of TL in
Figure 6. Splenic architecture is disrupted, with loss of contractile fibroblasts, in mice developing Amela-melanomas. Spleens from
control, Mela-, and Amela-bearing mice stained in (A) with ER-TR7/chicken anti-ratAlexa488 (left), anti-laminin/donkey anti-rabbit-Alexa488 (middle),
and anti-collagen IV/donkey anti-rabbit-Alexa488 (rigth) to detect stromal networks, and in (B) with anti-B220-FITC (green), anti-Desmin/donkey anti-
rabbit-Alexa555 (red). Representative of 5 mice per group.
doi:10.1371/journal.pone.0022639.g006
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shedding of CD62L, the L-selectin that directs naı ¨ve TL into LN
[44]. This activity was linked to increased expression of the
protease ADAM17 by the iMC/MDSC [44]. Down-regulation of
CD62L from TL also occurred in mice with inflammatory
melanoma (Fig.S6A), We even observed shedding of CD62L from
naı ¨ve polyclonal TL 24hrs after their transfer in Amela-bearing
mice (Fig.S6B). Since L-selectin is not implicated in TL homing to
the spleen, additional mechanisms are probably at play. In
particular, other protease activities have recently been found to be
exerted by iMC/MDSC [45]. We observed that transcripts for
MMP9, cathepsin G and neutrophil elastase are over-expressed in
spleens of Amela-bearing mice (Fig.S6C). Whether the corre-
sponding activities may contribute to the destruction of SLO
stromal cell networks remains to be established. Neutrophils,
which are known to degrade tissues by releasing matrix
metalloproteinases, have been described to participate in LN
remodeling during parasite infection [35]. We may speculate that
iMC/MDSC might similarly contribute to SLO remodeling in the
case of inflammatory tumors. Other mechanisms such as iMC-
induced apoptosis may also contribute to reduction of FRC,
notably by limiting factors involved in FRC homeostasis.
A striking result from this study is that inflammatory tumors
perturbed SLO architecture and rendered SLO non-receptive for
Figure 7. Gr1
+CD11b
+ cells recruited in SLO interact with the stroma in mice developing Amela-melanomas. LN (A) or spleen (B)
sections from control, Mela- and Amela-bearing mice were stained with anti-Gr1-PE (red) and anti-Lyve-1-biotyl/streptavidin-FITC (green) to detect LN
medullas or for MOMA-1 (green) to delineate splenic white pulp areas, respectively. LN (C) or spleen (D) sections from Amela-bearing mice were
stained with anti-Gr1-APC (green) and anti-ER-TR7/chicken anti-rat-Alexa647 (blue). Magnification showing a cluster of Gr1
+ cells on the stromal
network is shown.
doi:10.1371/journal.pone.0022639.g007
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It has been difficult to directly address the question of the role of
iMC in destruction of SLO architecture by their adoptive transfer
into hosts devoid of tumor influence, since these cells migrated to
the bone marrow, but not to the spleen and LN in these hosts
(Fig.S7A). Similarly, treatment with anti-Gr1 mAb failed to
eliminate the Gr1+CD11b+ population from aggressive inflam-
matory melanoma-bearing mice (Fig.S7B). This failure may be
related to the production by the Amela-tumors of factors such as
G-CSF implicated in recruitment of myeloid precursors from the
bone marrow, and of chemokines such as CCL2 known to recruit
iMC [17]. On the other hand, injection of isolated chemokines
(CCL2) / growth factors (VEGF) failed to reproduce the disrupted
phenotype of SLO observed in inflammatory melanoma-bearing
mice, although they might be contributing factors [43,46].
The recognition that SLO of inflammatory tumor-bearing hosts
are poorly receptive to CCR7-dependent migration of MigDC
and naı ¨ve TL may be relevant for proposed vaccination or
adoptive TL therapies applied to such tumors. The importance of
selecting tumor-specific TL with capacity for long-term survival for
adoptive therapy has recently been stressed [47]. Our data
indicate the additional importance of selecting TL with appropri-
ate tissue/tumor migratory properties, rather than CCR7
+ naı ¨ve
or memory TL that migrate to the T-zones of SLO, for treatment
of the autochthonous inflammatory tumors that we study. Indeed,
these tumors, in contrast to transplanted tumors [48], are poorly
infiltrated by either naı ¨ve or weakly activated transferred TL
[17,49]. Our studies are now aimed at designing anti-tumor TL
effectors with characteristics allowing them to migrate directly into
tumors and to resist the immunosuppressive tumor microenviron-
ment. This treatment, in combination with therapeutic antibodies
blocking TDF which either act directly on SLO (such as VEGF,
FGF-2), or act indirectly via the mobilization of iMC/MDSC [15],
may further contribute to restore the efficacy of the host’s
endogenous immune system.
Materials and Methods
Ethics statement
All procedures were approved by the Regional ‘‘Provence-
Alpes-Cote d’Azur’’ Committee on Ethics for Animal Experimen-
tation (authorization: #13.21, date: 11/02/2000) and were in
accordance with French and European directives.
Mice
We used TiRP-10B;Ink4a/Arf
flox/flox mice [16] backcrossed to
strain B10.D2/nOlaHsd (Harlan, Gannat, France) [17] that
develop either Mela- or Amela-melanomas after 4OH-tamoxifen
(Sigma) treatment ([17] and Text S1). Examples of mice with
induced Mela- or Amela-melanomas used in this study are shown
in Fig.S8. Age-matched TiRP-10B negative Ink4a/Arf
flox/flox
control mice, treated with 4OH-tamoxifen as the experimental
mice, never developed tumors because of the absence of the TiRP-
10B transgene [17]. Mice were housed under specific pathogen-
free conditions.
Immunohistology
Spleens, LN, skin or tumors were snap-frozen in Tissue Tek
(Sakura Finetek). Serial frozen sections (5- to 10-mm) were fixed in
acetone and stained with the indicated antibodies. Confocal
microscopy and image processing were performed, respectively,
with a Zeiss LSM 510 META microscope and Zeiss LSM
software. Immunofluorescence was quantified using NIH ImageJ
software for the determination of relative densities of expression of
given markers within fixed section areas (fraction area).
Adoptive transfer experiments
Naı ¨ve TL isolated from LN and spleens of B10.D2 mice were
labeled with the intra-cytoplasmic dye, carboxyfluorescein succi-
nimidyl ester (CFSE) (Molecular Probes) and 5610
6 of these cells
in 100 ml PBS were injected i.v. in mice, which were sacrificed
15 hrs later for analysis of migration by immunohistology.
DC isolation
LNs were cut in small pieces and incubated for 20 min with a
mixture of collagenase II (Worthington Biochemical) and DNAse
(Sigma-Aldrich) as described [20].
Assay of skin-derived DC migration
TRITC (Tetramethylrhodamine-5-(and-6)-isocyanate, Molecu-
lar Probe (Eugene, OR)), dissolved in a 50:50 (v/v) acetone-
dibutylphtalate mixture, was applied (30 ml of 10% TRITC) on
the tumor and shaved skin around the tumor for Amela-bearing
mice and on the equivalent shaved skin area of control mice.
Shaving was performed at least 24 hrs before skin-painting. Mice
were killed 20 hrs after painting and DC were isolated from LNs
and analyzed by fluorescence-activated cell sorter (FACS).
Flow cytometry
Before staining, cells were preincubated on ice with 2.4G2 mAb
to block Fc-receptors. For analysis of DC subpopulations, LN cell
suspensions were gated on CD11c
+NK1.1
2CD25
2CD45R
2 cells
and autofluorescent cells were gated out using the AmCyan
channel. FACS analysis was performed using the LSRII and data
were analyzed using DIVA software.
Antibodies
For FACS analysis, mAbs specific for CD161c (NK1.1)-APC-
H7, CD45R (RA3-6B2)-APC-H7, CD25 (PC61)-APC-H7,
CD197/CCR7 (4B12)-Biotin were from BD (Biosciences Phar-
mingen) and those specific for CD11c (N418)-PECy5.5 and MHC
class II (M5/114)-A700 were from eBioscience. For CD207/
langerin intracellular staining, mAb (929F3)-A647 (Abcys) was
used with the Cytofix/Cytoperm kit from BD.
For immunohistology, ER-TR7 mAb specific for an unknown
FRC-secreted molecule was from BMA. MAbs to Gr1 (RB6-8C5),
CD11b (M1/70), CD3 (2C11) and B220 (RA3-6B2) were from
BD, mAbs to Desmin, Collagen IV and Laminin from Abcam.
Anti-MOMA-1 (Cerdalane laboratories), anti-CCL21, anti-gp38
and anti-Lyve-1 (R&D system) antibodies were used. For
uncoupled primary antibodies, incubations were at 4uC overnight,
followed by secondary antibody for 45 min at room temperature.
For directly coupled antibodies, incubations were for 45 min at
room temperature. All combinations of primary and secondary
antibodies were pre-tested for specificity of labeling.
Quantitative RT-PCR
Total RNA was isolated from whole spleens (conserved at
280uC in RNA later) using RNeasy Mini Kit column purification
and digestion with RNase free DNaseI according to the
manufacturer’s protocols (Qiagen). cDNA was generated using
the SuperScriptH first-strand synthesis system for RT-PCR
according to the manufacturer’s instruction (Invitrogen). Quanti-
tative real time RT-PCR was performed with an Applied
Biosystem Prism 7500 fast real time PCR system using SYBR
green PCR Master Mix (Applied Biosystems). Results were
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Oligonucleotide sequences are reported in Table S2.
Statistics
Statistical analyses were performed with the Student’s t test
using GraphPad and two-tailed P values are given as: (*) P,0.1;
(**) P,0.01; and (***) P,0.001; (ns) P.0.1.
Supporting Information
Figure S1 Comparaison of representation of DC subsets
in LN from control, Mela- and Amela-bearing mice.
Analysis of DC subpopulations in TDLN (left) or non-draining LN
(NDLN) (right) from Amela- (A) or Mela- (B) bearing or LN from
control (C) mice. After gating on CD11c
+NK1.1
2CD
25
2CD45R
2 cells, CD11c versus MHCII staining identifies MigDC
(CD11c
+MHCII
high) and ResDC (CD11c
highMHCII
intermediate)a n d
shows a relative depletion of the MigDC population selectively in
TDLN ofAmela-bearing mice. (D)Immunohistology ofsections from
control LN, Mela-TDLN and Amela-TDLN showing anti-MHCII
(white), anti-B220 (green; B cells) and anti-CD3 (blue; T cells).
(PDF)
Figure S2 Similar level of CCR7 expression on TL from
control, Mela- or Amela-bearing mice. Spleen cells
harvested from control, Mela- or Amela-bearing mice were
stained with anti-CD3 and anti-CCR7 mAb. FACS analysis of
CCR7 expression within the CD3+ fraction is shown.
(PDF)
Figure S3 Modifications of the stromal network in
Amela-TDLN. LN sections from control mice and TDLN from
Mela- and Amela-bearing mice were stained with (A) anti-B220-
FITC (green), anti-Desmin/donkey anti-rabbit-Alexa555 (red) or
(B) with anti-ER-TR7/chicken anti-rat-Alexa647 (green) and anti-
Desmin/donkey anti-rabbit-Alexa555 (red). In (B) mice had
received 10
6 CFSE-labeled B10.D2 TL (withe), as in Fig.2,
20hrs before their sacrifice. In the magnification (left), the TL
(withe) can be seen to interact with the Desmin+ER-TR7+ FRC in
the Mela-TDLN.
(PDF)
Figure S4 Gr1
+CD11b
+ iMCs are recruited to SLOs and
tumor in Amela-bearing mice. Analysis of spleen (left), LN
(middle) and skin or tumor (right) sections from control mice
(upper) and Amela-bearing mice (lower). The sections were stained
for the proliferation marker Ki-67 (green), Gr1 (red) and the nuclei
marker Topro3 (blue) as described (Soudja et al. 2010).
(PDF)
Figure S5 Stromal cells present in the splenic red pulp
of Amela-bearing mice express the VEGFR2. Spleen
sections from control and from Amela-bearing mice were stained
with anti-collagen IV antibody (red) and with goat anti-
mouseVEGFR2 (Flk-1) antibody from R&D Systems (green).
Single stainings and merge images are shown. A magnification of
the merged image is shown (far rigth).
(PDF)
Figure S6 Potential mechanisms implicated in the
disruption of SLO in Amela inflammatory tumor-
bearing mice. (A) FACS analysis of CD62L expression on
CD8 TL from LN and spleens of control mice (black), Mela-
(blue), or Amela- (red) bearing mice. Mean fluorescence intensity
values were normalized to those of the control samples. (B) TL
from CD45.1 B10.D2 mice were purified and transferred in
control mice, Mela- or Amela-bearing mice (all of which are
CD45.2). 24 hrs later mice were sacrificed. FACS analysis of
CD62L expression on transferred TL from control mice (black
line), Mela- (blue line) or Amela- (red line) bearing mice is shown
for LN (left) and spleen (right) samples. Gray lines are for
unstained samples. (C) Quantitative RT-PCR for MMP9 (Mmp9),
Cathepsin G (Ctsg) and Elastase-2 (ELA-2, Cela2a) transcript
expression normalized to TBP (Tbp) mRNA expression in whole
spleens from control, Mela- or Amela-bearing mice.
(PDF)
Figure S7 iMCs retrieved from spleens of Amela-
bearing mice migrate to the bone marrow (BM) in
tumor-free mice and anti-Gr1 mAb treatment fails to
deplete them from Amela-bearing hosts. (A) Spleen cells
from Amela-bearing mice rich in iMCs were labeled with CFSE
10 mM and transferred in tumor-free or in induced Amela-bearing
mice. 20 hrs later LN, spleen and BM were harvested and FACS
analysis was performed on CFSE+ gated cells. % of CFSE+ cells
expressing Gr1 and CD11b (Gr1CD11b) or CD3 (T cells) is
indicated as the mean +/2 s.d. for 3 mice per group. Enrichment
in Gr1+CD11b+ cells in spleens and in LN was observed only in
Amela-tumor bearing mice. (B) Control and induced Amela-
bearing mice were treated with 300 mg anti-Gr1 mAb (RB6-8C5)
injected i.p. every 2 days for 6 days, were sacrificed at day 8 and
LN, spleen and BM cells were analyzed by FACS for expression of
CD11b and Ly-6G mAb (1A8), which recognizes an epitope of the
Ly-6G/Gr1 molecule that is distinct from that recognized by mAb
RB6-8C5. High percentages of CD11b+Ly62G+ (iMCs) were still
present in LN and spleen of Amela-bearing mice. Representative
of two mice per group.
(PDF)
Figure S8 Examples of TiRP-10B Ink4a/Arf
flox/flox
B10.D2 mice with induced pigmented Mela- or amela-
notic Amela-melanomas used in this study.
(PDF)
Table S1 conserved numbers of TL in spleens of mice
developing Amela-melanomas. (a) Spleen cells harvested from
control, Mela- or Amela-bearing mice were counted and stained for
CD45, CD4, CD8 and B220 expression by FACS as described (Soudja
et al. 2010). N= number of mice analyzed. (b) % CD45+ cells among
live spleen cells are given +/2 SD. Corresponding cell numbers are
g i v e ni nb o l d .( c )%C D 8T La m o n gC D 4 5 + spleen cells +/2 SD.
Corresponding cell numbers are given in bold. (d) % CD4 TL among
CD45+ spleen cells +/2 SD. Corresponding cell numbers are given in
bold. (e) % B220
+ cells among CD45+ spleen cells +/2 SD.
Corresponding cell numbers are given in bold.
(DOC)
Table S2 Murine primer sequences used in the real-
time QRT-PCR amplifications shown in Fig.4B and in
Fig.S6C.
(DOC)
Text S1 Mice. On the B10.D2 (B10.D2/nOlaHsd, H-2
d)
background, the TiRP-10B Ink4a/Arf
flox/flox B10.D2 mice housed
in the CIML facility develop, after 4OH-tamoxifen treatment
(injection s.c. twice two weeks apart of 4 mg 4OH-tamoxifen
dissolved in ethanol and brought to 20 mg/ml with autoclaved
sunflower oil as described (Huijbers et al. 2006)), single
melanomas, either strongly pigmented (Mela) or unpigmented
(Amela) with similar latency (on average 160 days) (Soudja et al.
2010). The incidence of Amela development was about 4 fold
higher than that of Mela tumors. Mela- and Amela-tumor bearing
mice analyzed in the present study each carried a single tumor, the
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examples, see Fig.S8.
(DOCX)
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